EP Patent

EP2289879A1 — Synthesis of a crytalline form of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide tartrate salt

Assigned to Acadia Pharmaceuticals Inc · Expires 2011-03-02 · 15y expired

What this patent protects

Disclosed herein are methods for synthesizing a crystalline form of hemitartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy) phenylmethyl)carbamide and methods for obtaining the salt.

USPTO Abstract

Disclosed herein are methods for synthesizing a crystalline form of hemitartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy) phenylmethyl)carbamide and methods for obtaining the salt.

Drugs covered by this patent

pimavanserin-tartrate (PIMAVANSERIN TARTRATE)

Patent Metadata

Patent number: EP2289879A1
Jurisdiction: EP
Classification: —
Expires: 2011-03-02
Drug substance claim: No
Drug product claim: No
Assignee: Acadia Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.